The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.